# A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

> **NCT00416520** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 336 (actual)

## Conditions studied

- Chronic Kidney Disease
- Hyperphosphatemia

## Interventions

- **DRUG:** MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)
- **DRUG:** Placebo
- **DRUG:** Another phosphate binder (Sevelamer)

## Key facts

- **NCT ID:** NCT00416520
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00416520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00416520, "A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00416520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*